Marshall Financial Group LLC Sells 29,354 Shares of Novo Nordisk A/S $NVO

Marshall Financial Group LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 84.0% during the second quarter, Holdings Channel.com reports. The institutional investor owned 5,607 shares of the company’s stock after selling 29,354 shares during the period. Marshall Financial Group LLC’s holdings in Novo Nordisk A/S were worth $269,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in NVO. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Novo Nordisk A/S by 5.1% during the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after purchasing an additional 717,719 shares during the last quarter. Morgan Stanley increased its stake in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after purchasing an additional 428,660 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $287,660,000. Institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk CEO Mike Doustdar said demand for weight-loss medicines still has a “long runway,” arguing that GLP-1 adoption remains in its early stages and could ultimately reduce healthcare costs and improve productivity. Novo Nordisk CEO sees long runway for weight-loss drugs
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, expanding the company’s diabetes portfolio and providing a potential new commercial growth driver beyond obesity treatments. Awiqli now available in the US
• Positive Sentiment: Erste Group raised its 2026 earnings-per-share estimate for Novo Nordisk to $3.27 from $3.20, while bullish commentary argues that the company’s broader cardiometabolic pipeline is being undervalued. Analysts raise Novo Nordisk earnings estimates
• Neutral Sentiment: Novo Nordisk is suing Eli Lilly over weight-loss-drug advertising. Management says the lawsuit is intended to ensure fair competition, but the dispute also highlights the intensifying rivalry between the two leading obesity-drug companies. Novo Nordisk CEO defends lawsuit against Eli Lilly
• Negative Sentiment: Analysts cited flat Wegovy sales, pricing challenges, pipeline setbacks and the risk that Eli Lilly is pulling ahead in the oral obesity market. These concerns, combined with the Berenberg downgrade, are weighing on sentiment toward NVO. Berenberg cuts Novo Nordisk as Lilly takes the oral market

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. BMO Capital Markets restated a “market perform” rating and issued a $47.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a report on Wednesday. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Trading Down 1.4%

NYSE NVO opened at $46.52 on Thursday. The stock’s 50-day simple moving average is $47.24 and its two-hundred day simple moving average is $44.61. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $207.71 billion, a price-to-earnings ratio of 11.37, a PEG ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. Research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. The ex-dividend date of this dividend is Monday, August 17th. This represents a dividend yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 42.79%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.